Skip to main content
Clinical Trials/JPRN-UMIN000010849
JPRN-UMIN000010849
Completed
未知

Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy - Study of add-on therapy with DPP-4 inhibitor in diabetic patients uncontrolled with BOT

Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine0 sites40 target enrollmentMay 31, 2013
ConditionsType 2 diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 31, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with a history of hypersensitivity to vildagliptin 2\)Patients with diabetic ketoacidosis, diabetic coma and type 1 diabetes 3\)Patients with severe liver dysfunction 4\)Patients with severe infection, perioperative and severe trauma 5\)Patients with moderate renal dysfunction or endstage renal disease on hemodialysis 6\)Patients with heart failure (NYHA/New York Heart Association stage 3 or severer) 7\)Pituitary insufficiency or adrenal insufficiency 8\)Patienst with diarrhea, vomiting, starvation and irregular food intake 9\)Patients with proliferative diabetic retinopathy 10\)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infectioHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09- Influenza due to certain identified influenza viruses
CTRI/2020/12/029575Central Council for Research in Unani Medicine
Recruiting
Phase 2
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.
IRCT20090613002027N21Mazandaran University of Medical Sciences60
Recruiting
Not Applicable
Assessment of the efficacy and safety of accessory nerve reconstruction using nerve regeneration inducing tube in neck dissection for patients with head and neck cancer - A Prospective Multicenter Clinical StudyHead and neck cancer
JPRN-UMIN000032336Yokohama City University12
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.
EUCTR2011-001493-25-ATovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-001493-25-DEovo Nordisk A/S420